Drugs / AC607
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01602328 Comparator | Jun 2012 → Jun 2014 | acute kidney injury | AlloCure Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01602328 ↗ |
| Modality | Cell therapy | “mesenchymal stem cells (MSCs) may be a promising candidate for AKI management” PMID 30484934 ↗ Nov 2018 |